A MENZIES School of Health Research study has provided further insight into the cost-effectiveness of a new malaria medication, tafenoquine, to treat vivax malaria.
Primaquine and tafenoquine are the two medications available to treat the liver stage of vivax malaria.
The study uncovered that tafenoquine was a cost-effective option when compared to seven days of primaquine treatment.
Learn more about how these findings can provide cost-effective treatments HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Jan 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Jan 24
